Sir,
Polyreactive antibodies are now recognized as a major component of the natural antibody repertoire. These antibodies can bind to a variety of structurally unrelated host and foreign antigens and, in the presence of complement, are capable of lysing bacteria and enhancing the phagocytosis of apoptotic cells. [1] [2] [3] Normal serum contains millions of polyreactive antibodies with different binding patterns and affinities. In order to quantify these antibodies, we used a 2,4-dinitrophenol (DNP) surrogate assay and showed that, in mice, stimulation of Toll-Like Receptors (TLRs) by their respective exogenous or endogenous ligands led to a substantial increase in the secretion of polyreactive antibodies. 4 It has been estimated that as much as 50% of serum IgM in mice and IgG in humans is polyreactive. 5 Although there have been a number of studies on natural antibodies in humans, 6, 7 relatively little is known about the quantity of polyreactive antibody in the serum of normal subjects, or patients with various diseases.
The present investigation was initiated to quantify the titer of polyreactive antibodies in sera of systemic lupus erythematosus (SLE) patients. Sixty-five sera from 53 patients with SLE (37þ/À years, 91% females), who fulfilled the 1997 ACR classification criteria for SLE, were studied. Sera from 30 age-and sex-matched healthy individuals (34þ/À12years, 77% females) served as normal controls.
A surrogate assay was used to measure polyreactive antibodies. After comparing a number of different molecules, dinitrophenol (DNP) was chosen as the surrogate because it is a synthetic molecule, not present in the environment, and individuals are not normally exposed to it. Therefore, if antibodies in sera bind to DNP, these antibodies would almost certainly have to be polyreactive antibodies. 3 In brief, ELISA plates were coated with DNP and serially two-fold dilutions of serum was used to determine the polyreactive antibody titer, and the titer is reported as the reciprocal of the highest serum dilution that produced an absorbance above the plate background activity. Serum immunoglobulin concentrations were determined by sandwich ELISA using a standard curve.
As seen in Figure 1 (a), the titer of polyreactive IgG antibody in SLE patients was significantly higher than in normal controls, but, in contrast, the concentration of serum IgG in SLE patients did not differ from that of normal controls (Figure 1(b) ). Of particular interest, the ratio of the polyreactive IgG antibody titer to the IgG concentration in the SLE patients was significantly higher than in the normal controls (Figure 1(c) ). This argues that the serum IgG of SLE patients contains more polyreactive IgG antibody than the serum of controls. In contrast to polyreactive IgG, the titer of polyreactive IgM antibody in the serum of SLE patients was higher, but not significantly higher, than in normal controls (Figure 1(e) ). Moreover, the concentration of serum IgM was significantly lower in SLE patients than in normal controls (Figure 1(f) ). However, the ratio of the polyreactive IgM antibody titer to the IgM serum concentration (Figure 1(g) ) was significantly higher in the SLE patients. This argues that the serum IgM of SLE patients contains more polyreactive IgM antibody than the serum of normal controls. Although there was a positive trend when comparing the titer of polyreactive antibodies and the SLEDAI score, it did not reach statistical significance (Figure 1(d) ). A positive trend was not found with polyreactive IgM (Figure 1(h) ), nor was there a statistically significant positive correlation between the titer of polyreactive IgG or polyreactive IgM and the titer of anti-dsDNA antibody or the level of serum complement (data not shown).
A possible explanation for the increase in the ratio of the serum polyreactive antibody titer to the serum IgG or IgM concentration in SLE patients may be related to chronic inflammation, excessive tissue destruction, or the inability to clear apoptotic cells. Tissue damage by any of these means could result in the release of a number of different endogenous TLR ligands 8 which could stimulate the secretion of polyreactive antibodies. To what extent the increase in polyreactive antibodies in SLE serum contributes to the Letter to the Editor S Gunti et al.
